Solid Biosciences (SLDB) Free Cash Flow (2017 - 2026)

Solid Biosciences has disclosed Free Cash Flow across 10 years of filings, most recently posting -$47.3 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$47.3 million, down 48.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$171.7 million (down 61.03% YoY), and the FY2025 annual result was -$156.3 million, down 56.32% from the prior year.
• Free Cash Flow came in at -$47.3 million for Q1 2026 at Solid Biosciences, up from -$53.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$16.2 million in Q2 2022 to a low of -$53.3 million in Q4 2025.
• The 5-year median for Free Cash Flow is -$27.5 million (2022), against an average of -$29.3 million.
• Across the five-year window, Free Cash Flow surged 35.79% in 2023 and slumped 79.92% in 2025, its largest moves.
• Solid Biosciences' Free Cash Flow stood at -$34.8 million in 2022, then surged by 35.79% to -$22.3 million in 2023, then plunged by 32.55% to -$29.6 million in 2024, then plunged by 79.92% to -$53.3 million in 2025, then climbed by 11.29% to -$47.3 million in 2026.
• The last three Free Cash Flow figures came in at -$47.3 million (Q1 2026), -$53.3 million (Q4 2025), and -$33.3 million (Q3 2025), per Business Quant data.